Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and ...

Medical compensation in Denmark is generally paid out by health authorities. Read more at straitstimes.com. Read more at ...

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...

Novo Nordisk offers a unique GARP investment opportunity, with strong growth catalysts and attractive valuation. Read here ...

That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Four patients in Denmark will receive compensation after developing serious eye conditions from the weight-loss and diabetes ...

This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Lower Blood Pressure? Key Takeaways: Ozempic® may lower ...

America wants to reduce its reliance on Chinese supply chains, since it remains in a trade war that is only temporarily on ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...